Patents Issued in July 25, 2019
  • Publication number: 20190225669
    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells.
    Type: Application
    Filed: January 18, 2019
    Publication date: July 25, 2019
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay
  • Publication number: 20190225670
    Abstract: The present invention in various aspects and embodiments, involves methods for treating Tie2-related vascular permeability by administering one or more collagen IV-derived biomimetic peptides and involves compositions for treating Tie2-related vascular permeability comprising one or more collagen IV-derived biomimetic peptides. Such peptides can promote the Tie2 agonist activities of Angiopoietin 2 (Ang2), thereby stabilizing vasculature and/or lymphatic vessels.
    Type: Application
    Filed: October 4, 2017
    Publication date: July 25, 2019
    Inventors: Niranjan B. Pandey, Adam Mirando, Aleksander S. Popel, Jordan J. Green
  • Publication number: 20190225671
    Abstract: Human or chimeric heavy chain-only antibodies are provided, in the native amino acid residue at the first position of the fourth framework region (FR4) of said HCAb is substituted by a different amino acid residue that is capable of disrupting a surface-exposed hydrophobic patch comprising or associated with the native amino acid residue at that position.
    Type: Application
    Filed: August 22, 2017
    Publication date: July 25, 2019
    Inventors: Wim van Schooten, Nathan Trinklein, Shelley Force-Aldred, Marianne Bruggemann, Mike Osborn
  • Publication number: 20190225672
    Abstract: A triple expression vector is disclosed for expressing an antibody molecule comprising an Fc domain in prokaryotic cells and in eukaryotic cells. The triple expression vector comprises a polynucleotide encoding an Fc domain; a polynucleotide encoding a phage coat protein; a cloning site for cloning genes encoding an antibody molecule or a part thereof wherein the antibody molecule or part thereof does not comprise an Fc domain; a prokaryotic secretion signal sequence and a eukaryotic secretion signal sequence, or a secretion signal sequence that drives efficient secretion in both prokaryotic and eukaryotic cells; a promoter for mediating expression in eukaryotic cells; and a stop codon for preventing expression of the phage coat protein in eukaryotic cells.
    Type: Application
    Filed: October 11, 2017
    Publication date: July 25, 2019
    Inventors: Maria Gonzales PAJUELO, Johannes Joseph Wilhelmus DE HAARD
  • Publication number: 20190225673
    Abstract: Embodiments of the disclosure include methods and compositions for treatment of a medical condition related to the liver, including at least viral infections and liver cancer, for example. In specific embodiments, immunotherapies are provided for delivering polynucleotides locally to the liver, wherein the polynucleotides encode particular gene products that include bispecific antibodies, including those that target certain liver antigens, for example.
    Type: Application
    Filed: September 29, 2017
    Publication date: July 25, 2019
    Inventors: Robert Layne Kruse, Karl-Dimiter Bissig, Stephen M. G. Gottschalk, Thomas C. T. Shum
  • Publication number: 20190225674
    Abstract: Described herein are methods and compositions for the rapid production of therapeutic molecules using an inducible cell culture system.
    Type: Application
    Filed: July 11, 2017
    Publication date: July 25, 2019
    Applicant: Massachusetts Institute of Technology
    Inventor: Timothy Kuan-Ta Lu
  • Publication number: 20190225675
    Abstract: Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant binding protein or a source of expression of the binding protein, wherein the binding protein neutralizes a disease agent that is a toxin, for example a Clostridium difficile toxin, a Shiga toxin, a ricin toxin, or an anthrax toxin.
    Type: Application
    Filed: January 2, 2019
    Publication date: July 25, 2019
    Applicant: TUFTS UNIVERSITY
    Inventor: CHARLES B. SHOEMAKER
  • Publication number: 20190225676
    Abstract: The combination of a first binding site specifically binding to a target associated with an eye disease and a second binding site specifically binding to a target influencing the retention in the eye a multispecific binder provides for improved intravitreal retention compared to a monospecific binder. The second binding site specifically binds to a compound/molecules found in the extracellular matrix (ECM) in vitreous humor/retina. This compound of the extracellular matrix has to be present in amounts allowing a sufficient loading/dose of the drug to be bound. It has been found that collagen, especially collagen II, is a suitable compound in the ECM in the vitreous humor for this purpose. Thus, herein is reported a multispecific binder comprising a first binding site specifically binding to a therapeutic ocular target, and a second binding site specifically binding to collagen II.
    Type: Application
    Filed: December 4, 2018
    Publication date: July 25, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Michael Huelsmann, Erhard Kopetzki
  • Publication number: 20190225677
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system and are based on rational design informed by examination of publicly available databases of human antibody sequences.
    Type: Application
    Filed: December 10, 2018
    Publication date: July 25, 2019
    Inventors: Maximiliano Vasquez, Michael Feldhaus, Tillman U. Gerngross, K. Dane Wittrup
  • Publication number: 20190225678
    Abstract: The present invention relates generally to an anti-C5 antibody or antigen binding fragment thereof for use in the prophylaxis or treatment of a complement related disease or disorder in a patient having a polymorphism in complement C5 protein.
    Type: Application
    Filed: June 1, 2017
    Publication date: July 25, 2019
    Inventors: Florian Muellershausen, Mark Milton, Leslie Ngozi Anuna Johnson
  • Publication number: 20190225679
    Abstract: The present invention relates to the use of tesidolumab for the prevention or treatment of transplant rejection and in particular antibody mediated rejection of allografts.
    Type: Application
    Filed: June 5, 2017
    Publication date: July 25, 2019
    Inventors: Florian Muellershausen, Matthias Meier, Alan Slade, Irina Baltcheva, Mark Milton
  • Publication number: 20190225680
    Abstract: The present disclosure relates to a neutralising epitope for Tenascin-C, and binding domains specific thereto, for example antibodies or binding fragments thereof, pharmaceutical compositions comprising the same and use of said antibodies, binding fragments or composition in treatment, in particular the treatment of an inflammatory disorder.
    Type: Application
    Filed: September 29, 2017
    Publication date: July 25, 2019
    Applicant: Nascient Ltd
    Inventors: Kim Midwood, Eric Culbert, Patrick John Hextall
  • Publication number: 20190225681
    Abstract: Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.
    Type: Application
    Filed: December 5, 2018
    Publication date: July 25, 2019
    Inventors: Paul ADAM, Eric BORGES, Robert RAUCHENBERGER, Gabriela WOCHNIK-VELTRUP
  • Publication number: 20190225682
    Abstract: The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a bispecific antibody comprising an IL-33 antigen binding domain of which (i) binds to and inhibits activation of, an IL-33 receptor, or (ii) specifically binds to IL-33 and inhibits IL-33 from binding to the IL-33 receptor, and a TNF antigen binding domain of which (i) binds to and inhibits activation of, a TNF receptor, or (ii) specifically binds to TNF and inhibits TNF from binding to the TNF receptor, wherein the bispecific antibody is effective to treat the patient.
    Type: Application
    Filed: August 31, 2017
    Publication date: July 25, 2019
    Inventors: Jagdeep Nanchahal, Glenn R. Larsen, Marc Feldmann
  • Publication number: 20190225683
    Abstract: Described herein are novel compositions, targeted therapeutic methods, and assays for neutralizing and/or inhibiting the activity of “oxazole-containing (OxC) compounds,” to prevent or delay the onset of epithelial barrier dysfunction and chronic inflammation associated with various disorders, such as colitis.
    Type: Application
    Filed: November 14, 2016
    Publication date: July 25, 2019
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Shankar S. IYER, Thomas GENSOLLEN, Amit GANDHI
  • Publication number: 20190225684
    Abstract: The present invention provides methods of reducing cutaneous scar formation by treating a cutaneous wound with a composition comprising a therapeutic agent that is a sodium channel blocker and/or an inhibitor of the Nax/SCN7A pathway. The present invention also provides wound cover components impregnated with such compositions, kits composed of such compositions with a wound dressing or sterile wipe, and mixtures of such compositions with a topical component (e.g., cream, ointment, or gel) suitable for application to a cutaneous wound. The present invention also provides compositions, kits, devices, and methods for treating skin conditions (e.g., dermatitis, psoriasis, or other skin conditions) with such compositions and devices. Examples of such therapeutic agents include, but are not limited to, an inhibitor of a gene or protein selected from: ENac, COX-2, PGE2, PI3K, PKB, Nax Prss8, IL-1?, IL-8, SAPK, Erk gene, p38 gene, PAR2, S100A8, S100A9, S100A12.
    Type: Application
    Filed: January 22, 2019
    Publication date: July 25, 2019
    Inventors: Wei Xu, Seok Jong Hong, Robert D. Galiano, Thomas A. Mustoe
  • Publication number: 20190225685
    Abstract: Provided are novel anti-DLL3 antibodies and antibody drug conjugates, and methods of using such anti-DLL3 antibodies and antibody drug conjugates to treat brain cancer.
    Type: Application
    Filed: January 24, 2019
    Publication date: July 25, 2019
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: KUMIKO ISSE, LAURA SAUNDERS
  • Publication number: 20190225686
    Abstract: It is an object of the present invention to provide an antibody specifically binding to GPR20-positive tumor cells such as GIST, a pharmaceutical product comprising the antibody and having therapeutic effects on a tumor, a method for treating a tumor using the aforementioned pharmaceutical product, and the like. It is another object of the present invention to provide an anti-GPR20 antibody having internalization activity, an antibody-drug conjugate containing the antibody, and the like.
    Type: Application
    Filed: January 16, 2018
    Publication date: July 25, 2019
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kenji IIDA, Takehiro HIRAI, Tomoko TERAUCHI, Kensuke NAKAMURA
  • Publication number: 20190225687
    Abstract: The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.
    Type: Application
    Filed: February 22, 2018
    Publication date: July 25, 2019
    Inventors: Lei Fang, Zhengyi Wang, Bingshi Guo, Jingwu Zang, Wenqing Jiang, Yongqiang Wang
  • Publication number: 20190225688
    Abstract: The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.
    Type: Application
    Filed: March 25, 2019
    Publication date: July 25, 2019
    Inventors: Carlos J. Bosques, James S. Huston, Jonathan C. Lansing, Leona E. Ling, James Meador, III, Daniel Ortiz, Laura Rutitzky
  • Publication number: 20190225689
    Abstract: The present invention relates to methods of treating cancers with antagonistic anti-PD-1 antibodies, formulations of the antagonistic anti-PD-1 antibodies and drug products of the anti-PD-1 antibodies.
    Type: Application
    Filed: January 18, 2019
    Publication date: July 25, 2019
    Inventors: Edward ATTIYEH, Kyounghwa BAE, James G. GREGER, Christine Lourdes MAYER, Hong XIE
  • Publication number: 20190225690
    Abstract: The present disclosure provides antibodies and antigen binding fragments against CTLA4, which can block the binding of CTLA4 to its ligand. The antibodies of disclosure provide agents for treating diseases, such as cancer.
    Type: Application
    Filed: October 10, 2016
    Publication date: July 25, 2019
    Inventors: Ziyong SUN, Man ZHOU, Wencui MA, Hongli MA, Wei CHEN
  • Publication number: 20190225691
    Abstract: Provided are anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-L1 antibodies, variants, mutants, or antigen binding fragments thereof, and related expression vectors, and host cells. Provided are methods of making anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
    Type: Application
    Filed: April 10, 2019
    Publication date: July 25, 2019
    Applicant: Shanghai Henlius Biotech Inc.
    Inventors: Weidong JIANG, Pei-Hua LIN, Chi-Ling TSENG
  • Publication number: 20190225692
    Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.
    Type: Application
    Filed: October 3, 2017
    Publication date: July 25, 2019
    Applicant: Juno Therapeutics, Inc.
    Inventors: James SISSONS, Cameron BRANDT, Alexandra CROFT, Allen EBENS, Haley PEPER, Dean Y. TOY, Brian BELMONT, Stephen GOLDFLESS, Yue JIANG, Timothy JOHNSTONE, David KOPPSTEIN, Hieu NGUYEN, Blythe SATHER, Sonia TIMBERLAKE
  • Publication number: 20190225693
    Abstract: Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.
    Type: Application
    Filed: January 25, 2019
    Publication date: July 25, 2019
    Applicant: Massachusetts Institute of Technology
    Inventors: Richard O. Hynes, Noor Jailkhani
  • Publication number: 20190225694
    Abstract: The present invention is directed to a cell culture obtainable from CHO DG44 cells which are capable of being cultured under serum-free or protein-free culture conditions, and which express a biosimilar antibody for the monoclonal antibody natalizumab. The present invention is further directed to a cell of said cell culture, a method for producing said biosimilar antibody, and the use of said cell in said method.
    Type: Application
    Filed: June 27, 2017
    Publication date: July 25, 2019
    Inventors: Piotr Marcin Zien, Matthew Christopher Cheeks, Tomasz Sitar, Kornelia Bogumila Wisniewska, Rafal Andrzej Derlacz
  • Publication number: 20190225695
    Abstract: The present invention relates to novel multi-functional polypeptides comprising at least two antigen binding sites specific for the CD11b and CD15 cell surface markers. The present invention further relates to a polypeptide, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, the present invention relates to polynucleotides encoding said polypeptides as well as to vectors comprising said polynucleotides and to host cells transformed therewith and their use in the production of said polypeptides. In addition, the present invention relates to compositions, preferably pharmaceutical and diagnostic compositions, comprising any of the afore-described polypeptides, polynucleotides or vectors as well as to kits comprising said compositions. A further object of the present invention is the use of said compositions for therapeutic, diagnostic and cell separation methods.
    Type: Application
    Filed: June 22, 2017
    Publication date: July 25, 2019
    Applicant: TRIMUNO THERAPEUTICS, INC.
    Inventors: Heather M. OSBORNE, Amara C. SIVA
  • Publication number: 20190225696
    Abstract: The invention provides a method of reducing the severity of, or treating, thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.
    Type: Application
    Filed: January 24, 2019
    Publication date: July 25, 2019
    Inventors: David MADDEN, Kathleen GABRIEL, Guido MAGNI, Richard WOODWARD
  • Publication number: 20190225697
    Abstract: An embodiment of the invention provides a chimeric antigen receptor (C AR) comprising an antigen binding domain specific for FLT3, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of a proliferative disorder, e.g., cancer, in a mammal and methods of treating or preventing a proliferative disorder, e.g., cancer, in a mammal are also disclosed.
    Type: Application
    Filed: May 26, 2017
    Publication date: July 25, 2019
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Service
    Inventors: Christopher D. Chien, Terry J. Fry
  • Publication number: 20190225698
    Abstract: An anti-CD27 antibody, an antigen-binding fragment thereof, and a medical use of the same are described. Further, provided are a chimeric antibody comprising a CDR of the anti-CD27 antibody, a humanized antibody, a pharmaceutical composition comprising a human anti-CD27 antibody or an antigen-binding fragment thereof, and use of the same as an anti-cancer drug. The present invention particularly relates to a human anti-CD27 antibody and use thereof in preparing a drug for treating a CD27-mediated disease or disorder.
    Type: Application
    Filed: September 28, 2017
    Publication date: July 25, 2019
    Inventors: Shude YAN, Jiahua JIANG, Lianshan ZHANG, Guoqing CAO
  • Publication number: 20190225699
    Abstract: The present invention relates to a brain delivery protein, comprising a target binding antibody which binds to a target in a mammalian brain; two carrier moieties, each of which being capable of monovalent interaction with a protein expressed on a blood brain barrier (BBB) endothelial cell, wherein each of said carrier moieties is linked to a C-terminal end of the target binding antibody. The present invention moreover relates to use of such brain delivery proteins in therapy or diagnosis or for research of e.g. neurodegenerative disorders, and other brain diseases.
    Type: Application
    Filed: July 13, 2017
    Publication date: July 25, 2019
    Applicant: BioArctic AB
    Inventors: Lars LANNFELT, Dag SEHLIN, Greta HULTQVIST, Stina SYVÄNEN
  • Publication number: 20190225700
    Abstract: Disclosed is a method for production of a fusion protein in which an antibody and a lysosomal enzyme are fused. The method comprises; (a) a step of culturing mammalian cells producing the fusion protein in a serum-free medium to let the mammalian cells secrete the fusion protein in the culture medium, (b) a step of collecting culture supernatant by removing the mammalian cells from the culture medium, and (c) a step of purifying the fusion protein from the culture supernatant by using a column chromatography employing as a solid phase a material to which a substance having affinity for the fusion protein has been bound, a column chromatography employing as a solid phase a material having affinity for the phosphate group, and a size exclusion column chromatography.
    Type: Application
    Filed: August 25, 2017
    Publication date: July 25, 2019
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Yuri Koshimura, Hiroyuki Sonoda, Miroslav Matev, Shinji Kakimoto, Tsuyoshi Fukui, Yukichi Hatano
  • Publication number: 20190225701
    Abstract: The compositions and methods described herein are based, in part, on the discovery that regulatory B cells (Bregs) differentially express a specific set of coinhibitory molecules, including TIGIT, LAG-3, PD-1, CTLA4, and TIM-3. The data described herein indicate that TIGIT is required for both Breg-mediated tolerance maintenance at the steady state, and inflammation restraint during autoimmune and inflammatory diseases. Accordingly, provided herein are compositions and methods targeting coinhibitory molecules, such as TIGIT, LAG-3, PD-1, CTLA4, and TIM-3, in B cells, as novel therapeutic strategies for modulating immune suppression and treating diseases mediated or impacted by immune suppression mechanisms, such as autoimmune diseases and cancers.
    Type: Application
    Filed: September 26, 2017
    Publication date: July 25, 2019
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Vijay K. Kuchroo, Sheng XIAO
  • Publication number: 20190225702
    Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to innate immune cells, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: October 13, 2017
    Publication date: July 25, 2019
    Inventors: Patrick BAEUERLE, Luke EVNIN, Jeanmarie GUENOT, Holger WESCHE
  • Publication number: 20190225703
    Abstract: Provided are antibodies that bind and inhibit CD73, are capable of increasing the proliferation of T cells in the presence of CD39-expressing B cells and ATP. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent cancer.
    Type: Application
    Filed: October 11, 2016
    Publication date: July 25, 2019
    Inventors: CHRISTOPHE CAUX, LAURENT GAUTHIER, NICOLAS GOURDIN, CHRISTINE MENETRIER-CAUX, CARINE PATUREL, IVAN PERROT
  • Publication number: 20190225704
    Abstract: [Problem] The present invention provides an antibody that binds to TMEM132A, an anticancer agent and a cancer test method. [Solution] An antibody that binds to TMEM132A.
    Type: Application
    Filed: August 14, 2017
    Publication date: July 25, 2019
    Inventors: Yasuhiro MATSUMURA, Masahiro YASUNAGA, Shinji SAIJO, Shingo HANAOKA
  • Publication number: 20190225705
    Abstract: The present invention in general relates to novel binding molecules, in particular antibodies and compositions and kits comprising the same. Said binding molecules are capable of binding to human Factor XI and hence envisaged to be particularly useful in inhibiting thrombosis without compromising hemostasis. The binding molecules, compositions and kits provided herein are therefore inter alia intended for treatment of thrombosis-related diseases and conditions. Moreover, polynucleotides encoding the binding molecules of the invention, vectors comprising said polynucleotides and host cells for producing the polynucleotides are provided herein.
    Type: Application
    Filed: September 18, 2017
    Publication date: July 25, 2019
    Applicants: Bayer Pharma Aktiengesellschaft, ARONORA INC.
    Inventors: Andreas WILMEN, Anja BUCHMÜLLER, Erik TUCKER
  • Publication number: 20190225706
    Abstract: The invention relates to a glycoprotein comprising an optionally fucosylated glycan according to formula (105) or (106), wherein Su(A)x is a modified sugar moiety comprising one or more functional groups A. Functional group A is independently selected from the group consisting of a thiol group, a halogen, a sulfonyloxy group, a halogenated acetamido group, a mercaptoacetamido group and a sulfonated hydroxyacetamido group. The invention also relates to a glycoprotein-conjugate wherein a glycoprotein according to the invention is conjugated to a molecule of interest. Said molecule of interest may for example be an active substance. The invention further relates to a process for the preparation of a modified glycoprotein, and to a method for the preparation of a glycoprotein-conjugate. The invention particularly relates to modified antibodies, antibody-conjugates, antibody-drug conjugates and methods for the preparation thereof.
    Type: Application
    Filed: August 28, 2018
    Publication date: July 25, 2019
    Applicant: SynAffix B.V.
    Inventors: Floris Louis VAN DELFT, Remon VAN GEEL, Maria Antonia WIJDEVEN, Jorge Merijn Mathieu VERKADE, Ryan HEESBEEN
  • Publication number: 20190225707
    Abstract: Phosphorylation and dephosphorylation of MENA and MENA isoforms regulates the metastatic activity of cancer cells. Administration of a MENA kinase inhibitor results in significant reduction in the development of cancer metastasis in established and developing tumors. Administration of a MENA kinase inhibitor in conjunction with a tyrosine kinase inhibitor enhances efficacy of tyrosine kinase inhibitor therapy. Administration of a MENA kinase inhibitor in conjunction with anti-microtubule agent results in significant reduction in chemotherapy-induced tumor cell dissemination and enhances efficacy of anti-microtubule therapy.
    Type: Application
    Filed: July 7, 2017
    Publication date: July 25, 2019
    Inventors: Douglas A. HAMILTON, Anna L. BLOIS
  • Publication number: 20190225708
    Abstract: The present invention relates to variant antibodies and methods of generating said antibodies with a reduced level of binding to process impurities. In particular, the invention describes variant IgG4 antibodies which have been modified in the heavy chain constant region at any one or a combination of amino acids in the region between Kabat residues 203 and 256, wherein the variant IgG4 antibody has a reduced level of binding to host cell protein (HCP), compared to an unmodified IgG4 antibody. The invention also relates to compositions comprising said variant IgG4 antibodies.
    Type: Application
    Filed: October 3, 2017
    Publication date: July 25, 2019
    Inventors: Hella BOSTEELS, Shugui CHEN, Kayeleigh FARROW, Richard KUCIA-TRAN, William John Kenneth LEWIS, Andrew S. THOMSON, Mark UDEN
  • Publication number: 20190225709
    Abstract: The disclosure provides for single chain variable fragments to MAA-oxidized specific epitopes (OSEs). The disclosure also provides single chain virable fragments that bind to MDA-OSEs or MAA-OSEs on oxidized phospholipids and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents.
    Type: Application
    Filed: September 7, 2017
    Publication date: July 25, 2019
    Inventors: Sotirios Tsimikas, Joseph Witztum, Xuchu Que
  • Publication number: 20190225710
    Abstract: The invention relates to multimers such as tetramers of polypeptides and tetramers and octamers of effector domains, such as antigen binding sites (eg, antibody or TCR binding sites that specifically bind to antigen or pMHC, or variable domains thereof) or peptides such as incretin, insulin or hormone peptides.
    Type: Application
    Filed: September 18, 2017
    Publication date: July 25, 2019
    Inventors: Hanif ALI, Terence RABBITTS, Christian GRØNDAHL, Jasper CLUBE
  • Publication number: 20190225711
    Abstract: The present invention provides constructs comprising a plurality of peptides capable of targeting at least two different extracellular tumor antigens and a toxin, optionally connected to an organic scaffold. Use of such constructs in treating cancer are provided as well. The invention also provides particular peptides binding certain extracellular tumor antigens as well as toxins having antitumor activity.
    Type: Application
    Filed: September 27, 2017
    Publication date: July 25, 2019
    Inventors: Ilan MORAD, Hanan ITZHAKI
  • Publication number: 20190225712
    Abstract: A fine cellulose fiber composite in which a modifying group is bound to a carboxy group of fine cellulose fibers, the fine cellulose fibers having a carboxy group content of 0.1 mmol/g or more, wherein the fine cellulose fiber composite has an average aspect ratio of 1 or more and 150 or less; and a resin composition containing the fine cellulose fiber composite and a resin. The resin composition containing a fine cellulose fiber composite of the present invention has excellent heat resistance, and the molded article of this resin composition has excellent mechanical strength, heat resistance, and dimensional stability. Accordingly, the present invention can be suitably used in various industrial applications such as daily sundries, household electric appliance parts, wrapping materials for household electric appliance parts, and automobile parts.
    Type: Application
    Filed: August 4, 2017
    Publication date: July 25, 2019
    Applicant: KAO CORPORATION
    Inventors: Kyohei YAMATO, Yutaka YOSHIDA
  • Publication number: 20190225713
    Abstract: The invention relates to a method for polymerizing acrylates using a reactor (50). Reaction heat produced in the reactor (50) is discharged via a boiling cooler (40) in that gaseous vapors produced in the reactor (50) are supplied to the boiling cooler (40), and condensed vapors are returned to the reactor (50) from the boiling cooler (40). At least one component containing acrylate is at least partly added via the boiling cooler (40) and reaches the reactor (50) via the boiling cooler (40). The invention additionally relates to a system for polymerizing an acrylate, comprising a reactor (50) and a boiling cooler (40) for discharging reaction heat produced in the reactor (50). The boiling cooler (40) has at least one filling opening (46) for supplying at least one component containing acrylate.
    Type: Application
    Filed: September 5, 2017
    Publication date: July 25, 2019
    Inventors: Wolfgang FISCHER, Peter ITTEMANN, Florian PATCAS, Michael RUF
  • Publication number: 20190225714
    Abstract: The present invention relates to a reactor system for a multimodal polyethylene polymerization process, comprising; (a) a first reactor; (b) a hydrogen removal unit arranged between the first reactor and a second reactor comprising at least one vessel connected with a depressurization equipment, preferably selected from vacuum pump, compressor, blower, ejector or a combination thereof, the depressurization equipment allowing to adjust an operating pressure to a pressure in a range of 100-200 kPa (abs); (c) the second reactor; and (d) a third reactor and use thereof as a sheet.
    Type: Application
    Filed: September 11, 2017
    Publication date: July 25, 2019
    Applicants: Thai Polyethylene Co., Ltd., SCG Chemicals Co., Ltd.
    Inventors: Chatchai JARUMANEEROJ, Saranya TRAISILANUN, Watcharee CHEEVASRIRUNGRUANG, Piyawan TIYAPIBOONCHAIYA
  • Publication number: 20190225715
    Abstract: The invention relates to a process for preparing a solid support for a procatalyst suitable for preparing a catalyst composition for olefin polymerization, said process for preparing said solid support comprising reacting a compound R42MgX42-z with a silane compound Si(OR5)4-n(R6)n in a solvent and mixing the resulting mixture with a mixing device and at a certain mixing speed in order to give a solid support Mg(OR1)xX12-x said solid support obtained having an average particle size of at most 17 ?m, preferably at most 16 or 14 ?m, more preferably at most 12 ?m. The invention further relates to a solid support, a process for preparing a procatalyst and said procatalyst as well as polyolefins obtained using said procatalyst.
    Type: Application
    Filed: October 11, 2017
    Publication date: July 25, 2019
    Inventors: Akhlaq Moman, Inaamul Haq Siddiqui, Sudhakar R. Padmanabhan, Abdulaziz Hamad Al-Humydi
  • Publication number: 20190225716
    Abstract: The present invention relates to a procatalyst comprising the compound represented by formula A as an internal electron donor, Formula A wherein R is hydrogen or a methyl group, N is nitrogen atom; O is oxygen atom; and C is carbon atom. The present invention also relates to a process for preparing said polymerization procatalyst and to a polymerization catalyst system comprising said procatalyst, a co-catalyst and optionally an external electron donor. Furthermore, the present invention relates to a polyolefin obtainable by the process according to the present invention and to the use of the compound of formula A as in internal electron donor in catalysts for polymerization of olefins.
    Type: Application
    Filed: September 29, 2017
    Publication date: July 25, 2019
    Inventors: Jaiprakash Brijlal Sainani, Akhlaq Moman
  • Publication number: 20190225717
    Abstract: The present invention relates to a process for the production of a polymer using a compound comprising at least 2 unsaturated carbon-carbon bonds, wherein the process comprises a polymerisation section and a purification section, wherein the product from the polymerisation section is subjected in the purification section to a sequence of purification steps comprising: ?removal of the vapour phase from the product from the polymerisation section by means of flash separation to obtain a first vapour phase and a polymerisation product; ?subjecting the first vapour phase to a compression and condensation treatment to obtain a second vapour phase and a condensed monomer phase; wherein the purification steps are conducted in this order. Such process allows for the optimal utilisation of raw materials in the polymerisation process.
    Type: Application
    Filed: August 21, 2017
    Publication date: July 25, 2019
    Inventors: Ahmed Abouelfetouh Youssef, Vern Lowry, Dane Ferraris
  • Publication number: 20190225718
    Abstract: The present invention relates to a procatalyst comprising the compound represented by formula A as an internal electron donor (Formula A), wherein R is hydrogen or a methyl group, N is nitrogen atom; O is oxygen atom; and C is carbon atom. The present invention also relates to a process for preparing said polymerization procatalyst and to a polymerization catalyst system comprising said procatalyst, a co-catalyst and optionally an external electron donor. Furthermore, the present invention relates to a polyolefin obtainable by the process according to the present invention and to the use of the compound of formula A as in internal electron donor in catalysts for polymerization of olefins.
    Type: Application
    Filed: September 29, 2017
    Publication date: July 25, 2019
    Inventors: Jaiprakash Brijlal Sainani, Akhlaq Moman